Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?
Publication
, Journal Article
Wagner, LM
Published in: Clin Sarcoma Res
2015
Over the past 15 years, irinotecan has emerged as an important agent for treating pediatric sarcoma patients. This review summarizes the activity noted in previous studies, and outlines current issues regarding scheduling, route of administration, and amelioration of side effects. Also discussed are new pegylated and nanoliposomal formulations of irinotecan and its active metabolite, SN-38, as well as future plans for how irinotecan may be used in combination with other conventional cytotoxic as well as targeted agents.
Duke Scholars
Published In
Clin Sarcoma Res
DOI
ISSN
2045-3329
Publication Date
2015
Volume
5
Start / End Page
20
Location
England
Related Subject Headings
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Wagner, L. M. (2015). Fifteen years of irinotecan therapy for pediatric sarcoma: where to next? Clin Sarcoma Res, 5, 20. https://doi.org/10.1186/s13569-015-0035-x
Wagner, Lars M. “Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?” Clin Sarcoma Res 5 (2015): 20. https://doi.org/10.1186/s13569-015-0035-x.
Wagner LM. Fifteen years of irinotecan therapy for pediatric sarcoma: where to next? Clin Sarcoma Res. 2015;5:20.
Wagner, Lars M. “Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?” Clin Sarcoma Res, vol. 5, 2015, p. 20. Pubmed, doi:10.1186/s13569-015-0035-x.
Wagner LM. Fifteen years of irinotecan therapy for pediatric sarcoma: where to next? Clin Sarcoma Res. 2015;5:20.
Published In
Clin Sarcoma Res
DOI
ISSN
2045-3329
Publication Date
2015
Volume
5
Start / End Page
20
Location
England
Related Subject Headings
- 3211 Oncology and carcinogenesis